ETOPOSIDE PHOSPHONATE, ETOPOPHOS
Etoposide Phosphate
CAS: 117091-64-2
Molecular Formula: C29H33O16P
ETOPOSIDE PHOSPHONATE, ETOPOPHOS - Names and Identifiers
| Name | Etoposide Phosphate |
| Synonyms | ETOPOPHOS ETOPOSIDE PHOSPHATE Etoposide Phosphate Etoposide phosphate ETOPOSIDE PHOSPHONATE Etoposide 4'-Phosphate ETOPOSIDE PHOSPHONATE, ETOPOPHOS BMY-40481, Etoposide 4'-Dihydrogenphosphate |
| CAS | 117091-64-2 |
| EINECS | 630-364-1 |
ETOPOSIDE PHOSPHONATE, ETOPOPHOS - Physico-chemical Properties
| Molecular Formula | C29H33O16P |
| Molar Mass | 668.54 |
| Density | 1?+-.0.1 g/cm3(Predicted) |
| Boling Point | 907.7±75.0 °C(Predicted) |
| pKa | 1.13±0.50(Predicted) |
| Storage Condition | -20°C |
| In vitro study | Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule.Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW +/+ , FBXW -/- and p53 -/- as a dose-dependent manner, exhibits IC 50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively.Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7 -/- cells. Cell Viability Assay Cell Line: FBXW +/+ , FBXW -/- and p53 -/- cell Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM Incubation Time: 72 hours Result: Inhibited HCT116 FBXW +/+ , FBXW -/- and p53 -/- cell growth as a concentration manner. Western Blot Analysis Cell Line: HCT116 FBXW7 +/+ or FBXW7 -/- cells Concentration: 25 μM Incubation Time: 6 hours Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7. |
| In vivo study | Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8in female CD-1 mice. Animal Model: Female CD-1 mice Dosage: 50, 100, or 150 mg/kg Administration: Intravenous injection; single dose Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM). |
ETOPOSIDE PHOSPHONATE, ETOPOPHOS - Reference Information
| anti-tumor drug | etoposide phosphate is phosphate of etoposide, etoposide is a semi-synthetic derivative of podophyllotoxin, a cell cycle specific anti-tumor drug that acts on late S phase or G2 phase, and its action site is isomerization topoenzyme II, the formation of a stable cleavage complex between the drug-enzyme-DNA makes it difficult to repair the instantaneous strand breaks generated during DNA replication, leading to etoposide dose-dependent DNA damage in cells and promoting apoptosis. It is widely used to treat various malignant tumors, including leukemia, lymphoma and solid tumors, but it should be noted that the drug has severe bone marrow suppression and gastrointestinal reactions. |
| etoposide | etoposide is developed and listed by the American pharmaceutical giant Shimei Squibb Company. It is internationally recognized as a new anti-tumor drug and the most successful podophyllotoxin anti-tumor drug so far. Etoposide is a sugar metabolite of podophyllotoxin. It is a cell cycle specific anti-tumor drug. It acts on DNA topoisomerase II to form a drug-enzyme-DNA stable reversible complex, which hinders DNA repair and exerts anti-tumor effect. Etoposide combined treatment of recurrent ovarian cancer has achieved a more ideal short-term effect than cisplatin or carboplatin-based combined chemotherapy. The treatment of advanced gastric cancer in the elderly has always been a thorny problem. Etoposide shows a better treatment prospect. In March 2020, "I drug" duvaliumab combined with standard therapy (SoC), etoposide carboplatin or cisplatin chemotherapy was approved by FDA for the first-line treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC). In 2018, the total global sales of etoposide capsules were about US $26.23 million and the domestic sales were about US $2.62 million. |
| Biological activity | Etoposide phosphate (BMY-40481) is an effective anti-cancer chemotherapy reagent and A selective topoisomerase II (topoisomerase II) inhibitor can prevent DNA chain reconnection. Etoposide phosphate is a phosphate prodrug of etoposide and is considered to be comparable to Etoposide activity. Etoposide phosphate induce cell cycle arrest, apoptosis (apoptosis) and autophagy (autophagy). |
| target | Topoisomerase II |
| in vitro study | Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4 'of the E ring of the etoposide molecule.Etoposide phosphate (0-1 μ M; 72 hours) inhibits HCT116 FBXW / , FBXW -/- and p53 -/- as a dose-dependent manner, exhibits IC 50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively.Etoposide phosphate (25 μM; 6 hours) dails p53 recover in FBXW7-deficient cells. in addition, FBXW7 expression is disappeared in FBXW7 -/- cells. cell Viability Assay Cell line: FBXW / , FBXW -/- and p53 -/- cell Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM Incubation Time: 72 hours Result: Inhibited HCT116 FBXW / , FBXW -/- and p53 -/- cell growth as a concentration manner. Western Blot Analysis Cell Line: HCT116 FBXW7 / or FBXW7 -/- cells Concentration: 25 μM Incubation Time: 6 hours result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7. |
| Cell Line: | FBXW / , FBXW -/- and p53 -/- cell HCT116 FBXW7 / or FBXW7 -/- cells |
| Concentration: | 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM 25 μM |
| Incubation Time: | 72 hours 6 hours |
| Result: | Inhibited HCT116 FBXW / , FBXW -/- and p53 -/- cell growth as a concentration manner. Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7. Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM). |
| in vivo study | Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8in female CD-1 mICE. animal model: female CD-1 mICE Dosage: 50, 100, or 150 mg/kg Administration: Intravenous injection; Single dose Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM). |
| Animal Model: | Female CD-1 mice |
| Dosage: | 50, 100, or 150 mg/kg |
| Administration: | Intravenous injection; single dose |
Last Update：2024-04-09 02:00:00
Supplier List
Spot supply
Product Name: Etoposide Impurity 22 Visit Supplier Webpage Request for quotationCAS: 117091-64-2
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Etoposide Phosphate Visit Supplier Webpage Request for quotation
CAS: 117091-64-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 117091-64-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Etoposide Impurity 22 Visit Supplier Webpage Request for quotationCAS: 117091-64-2
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Etoposide Phosphate Visit Supplier Webpage Request for quotation
CAS: 117091-64-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 117091-64-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History
ETOPOSIDE PHOSPHONATE, ETOPOPHOS
山奈酚-7-葡萄糖醛酸苷
Moxifloxacin Impurity S
Fmoc-T(Trt)-OH
2375919-20-1
174800-19-2
199540-45-9
22438-61-5
山奈酚-7-葡萄糖醛酸苷
Moxifloxacin Impurity S
Fmoc-T(Trt)-OH
2375919-20-1
174800-19-2
199540-45-9
22438-61-5